← Back to Screener
Vera Therapeutics, Inc. Class A Common Stock (VERA)
Price$33.94
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)11.52%
Price vs S&P 500 (4W)-4.06%
VGM Score58.56
Market Capitalization$2.45B
All Metrics
Book Value / Share (Quarterly)$6.97
P/TBV (Annual)7.81x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.10
Price vs S&P 500 (YTD)-40.79%
EPS (TTM)$-5.54
10-Day Avg Trading Volume0.99M
EPS Excl Extra (TTM)$-5.54
EPS (Annual)$-4.66
ROI (Annual)-44.10%
Cash / Share (Quarterly)$8.32
ROA (Last FY)-40.78%
EBITD / Share (TTM)$-5.79
ROE (5Y Avg)-66.60%
Cash Flow / Share (Annual)$-3.39
P/B Ratio4.90x
P/B Ratio (Quarterly)5.77x
Net Income / Employee (Annual)$-1,203,300
Net Interest Coverage (TTM)-3260.00x
ROA (TTM)-60.18%
EPS Incl Extra (Annual)$-4.66
Current Ratio (Annual)13.64x
Quick Ratio (Quarterly)13.36x
3-Month Avg Trading Volume1.13M
52-Week Price Return78.22%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.78
52-Week High$56.05
EPS Excl Extra (Annual)$-4.66
CapEx CAGR (5Y)44.50%
26-Week Price Return27.45%
Quick Ratio (Annual)13.48x
13-Week Price Return-16.13%
Total Debt / Equity (Annual)0.12x
Current Ratio (Quarterly)13.64x
Enterprise Value$2.41B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$10.03
3-Month Return Std Dev49.92%
Net Income / Employee (TTM)$-1,481,700
ROE (Last FY)-49.56%
Net Interest Coverage (Annual)-338.40x
EPS Basic Excl Extra (Annual)$-4.66
Total Debt / Equity (Quarterly)0.15x
EPS Incl Extra (TTM)$-5.54
ROI (TTM)-65.00%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.77
Price vs S&P 500 (52W)50.02%
Year-to-Date Return-29.86%
5-Day Price Return4.35%
EPS Normalized (Annual)$-4.66
ROA (5Y Avg)-45.08%
Month-to-Date Return-0.25%
EBITD / Share (Annual)$-4.90
LT Debt / Equity (Annual)0.12x
ROI (5Y Avg)-52.60%
LT Debt / Equity (Quarterly)0.15x
EPS Basic Excl Extra (TTM)$-5.54
P/TBV (Quarterly)4.85x
P/B Ratio (Annual)5.87x
Book Value / Share (Annual)$8.48
Price vs S&P 500 (13W)-25.87%
Beta0.91x
Revenue / Share (TTM)$0.00
ROE (TTM)-74.86%
52-Week Low$18.76
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.69est. -1.35
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.15
4.15
4.25
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VERAVera Therapeutics, Inc. Class A Common Stock | — | — | C | $33.94 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Vera Therapeutics is a clinical-stage biotech company developing atacicept, a once-weekly subcutaneous fusion protein designed to treat serious autoimmune diseases. The drug works by blocking two key drivers of autoimmune dysfunction—B lymphocyte stimulator and APRIL—which reduces B cell and plasma cell activity and autoantibody production. The company is advancing atacicept through clinical development with a focus on transformative therapeutic potential in immunological disorders.